### Learner Notification

**MED Learning Group**

**Weight No Longer: Addressing Overweight/Obesity as an Integral Part of Type 2 Diabetes Management**

**January 4, 2024 – March 26, 2024**

**Online**

**Acknowledgement of Financial Commercial Support**

Lilly

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Utilize guidelines and clinical data supporting a weight-centric approach to the treatment of patients with type 2 diabetes.
2. Select pharmacological agents that facilitate both weight management and glycemic control.
3. Implement shared decision-making strategies to help patients with type 2 diabetes select and follow through with informed options for weight loss.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Russie | Allen | NA |
| Millena | De Brito | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Amanda | Jenkins | NA |
| Melissa A. | Johnson | NA |
| Davida | Kruger | Novo Nordisk, Lilly, Abbott, Embecta, CeQur Corporation, Mannkind Corporation, Medtronic, Sanofi: Consultant, Lilly, Novo Nordisk, Dexcom, CeQur Corporation, Sanofi, Xeris: Speakers Bureau, Abbott, Beta Bionics, Insulet, Novo, and Tandem: Contracted Research |
| Cindy | Lampner | NA |
| Joshua J. | Neumiller | Sanofi, Bayer, Boehringer Ingelheim, Eli Lilly: Consultant, Dexcom: Speakers Bureau |
| Lucia M. | Novak | Abbott Diabetes Care, Ascencia, Boehringer Ingelheim, Medtronic, Novo Nordisk: Consultant, Abbott Diabetes Care, Boehringer, Ingelheim/Eli Lilly Alliance, Novo Nordisk: Speakers Bureau |
| Anne | Peters | Vertex, Lily, Medscape, Abbott: Consultant, Insulet, Abbott Diabetes Care: Contracted Research, Teladoc, Omada Health: Ownership Interest |
| Kim | Pfotenhauer | Abbott Laboratories: Consultant |
| Richard | Pratley | NA |
| Jay H. | Shubrook | Dompe, NovoNordisk: Grants, Abbott, Bayer, Novo Nordisk: Consultant, Astra Zeneca, Eli Lilly, Nevro: Scientific/Medical Advisory Board |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email Certificate@AmedcoEmail.com